Safety and efficacy of nivolumab in patients who failed to achieve a complete remission after CD19-directed CAR T-cell therapy in diffuse large B cell lymphoma. - Université de Lille Accéder directement au contenu
Article Dans Une Revue British Journal of Haematology Année : 2023

Safety and efficacy of nivolumab in patients who failed to achieve a complete remission after CD19-directed CAR T-cell therapy in diffuse large B cell lymphoma.

Dates et versions

hal-04143828 , version 1 (28-06-2023)

Identifiants

Citer

Nicolas Gazeau, Suman Mitra, Morgane Nudel, Remi Tilmont, Paul Chauvet, et al.. Safety and efficacy of nivolumab in patients who failed to achieve a complete remission after CD19-directed CAR T-cell therapy in diffuse large B cell lymphoma.. British Journal of Haematology, 2023, British Journal of Haematology, ⟨10.1111/bjh.18775⟩. ⟨hal-04143828⟩
18 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More